FY2030 Earnings Estimate for Geron Issued By HC Wainwright

Geron Corporation (NASDAQ:GERN) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Geron in a research note issued on Monday, January 12th. HC Wainwright analyst E. Bodnar anticipates that the biopharmaceutical company will post earnings of $0.58 per share for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $47.23 million during the quarter, compared to the consensus estimate of $55.24 million. Geron had a negative return on equity of 29.63% and a negative net margin of 43.61%.

Other equities research analysts have also issued reports about the stock. Needham & Company LLC reduced their target price on shares of Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. UBS Group reiterated a “neutral” rating on shares of Geron in a report on Tuesday, December 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a research note on Friday, October 31st. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Geron has an average rating of “Hold” and a consensus price target of $2.75.

Geron Stock Performance

Geron stock opened at $1.30 on Wednesday. The business has a 50 day moving average of $1.27 and a 200-day moving average of $1.30. The company has a market capitalization of $829.86 million, a P/E ratio of -10.83 and a beta of 0.59. Geron has a 1 year low of $1.04 and a 1 year high of $3.12. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.96 and a quick ratio of 4.87.

Institutional Investors Weigh In On Geron

Institutional investors have recently modified their holdings of the company. StoneCrest Wealth Management Inc. acquired a new stake in shares of Geron during the second quarter worth $35,000. Swiss Life Asset Management Ltd boosted its position in Geron by 73.6% during the third quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 11,182 shares during the last quarter. Savant Capital LLC boosted its position in Geron by 73.8% during the second quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 11,074 shares during the last quarter. Fisher Asset Management LLC acquired a new stake in Geron during the 3rd quarter worth about $37,000. Finally, Summit Financial Strategies Inc. bought a new position in shares of Geron in the 2nd quarter worth about $38,000. 73.71% of the stock is owned by institutional investors.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.